Reply to the letter [0.03%]
致某人的回信
Jun Ehara,Sachiko Ohde,Shigeki Fujitani
Jun Ehara
ALT Reduction Following Pemafibrate Treatment in MASLD and MetALD with Dyslipidemia: Associations with the Baseline Liver Enzyme Levels [0.03%]
pemafibrate治疗MASLD和MetALD合并血脂异常患者的ALT水平降低与基线肝酶水平的关系
Takako Nomura,Masafumi Ono,Kiyoyuki Kobayashi et al.
Takako Nomura et al.
Objective Pemafibrate improves the liver function and lipid profiles in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). However, the data on metabolic dysfunction and alcohol-associated steatotic liver diseas...
Marked Response to Nivolumab Plus Ipilimumab After the Failure of Two Prior Immune Checkpoint Inhibitor-Based Regimens Including CTLA-4 Blockade in Advanced Hepatocellular Carcinoma [0.03%]
先前免疫检查点抑制剂治疗失败后的晚期肝细胞癌患者使用纳武利尤单抗联合伊匹木单抗的疗效：接受过CTLA-4阻断治疗患者的疗效分析
Shinichiro Minami,Wataru Sato,Kenjiro Yamamoto et al.
Shinichiro Minami et al.
Immune checkpoint inhibitor (ICI)-based combination therapies are standard treatments for advanced hepatocellular carcinoma (HCC). However, the efficacy of sequential ICI regimens remains unclear. We report the case of a 59-year-old woman w...
Comparable Clinical Characteristics and Outcomes between Patients with Total and Subtotal Coronary Occlusion during Intracoronary Acetylcholine Provocation Testing [0.03%]
冠脉内注射乙酰胆碱激发试验中完全闭塞与不完全闭塞性心肌缺血的临床特征及预后对比研究
Kota Usami,Yuichi Saito,Shunsuke Nakamura et al.
Kota Usami et al.
Background Intracoronary acetylcholine (ACh) provocation testing is a guideline-recommended diagnostic procedure for vasospastic angina (VSA). Although significant ACh-induced vasospasm is usually defined as either total or subtotal coronar...
Isavuconazole Therapy for Nasal-Cerebral Mucormycosis with High Isavuconazole MIC [0.03%]
伊萨康唑治疗对伊沙立康唑MIC值高的鼻脑黏菌病的效果研究
Takeo Mori,Kazuhisa Kamiyama,Sakura Koyama et al.
Takeo Mori et al.
Mucormycosis is a severe infection that requires prompt antifungal therapy. Although liposomal amphotericin B (L-AMB) is the standard treatment, its toxicity may limit its use. We report the case of a patient with diabetes mellitus and rhin...
Successful Treatment with Epcoritamab for Refractory Diffuse Large B-cell Lymphoma in a Dialysis-dependent Patient [0.03%]
终末期肾病患者难治性弥漫大B细胞淋巴瘤接受Epcoritamab治疗后获得完全缓解
Yuya Sasaki,Keisuke Tanaka,Hisako Nakamaki et al.
Yuya Sasaki et al.
The efficacy of epcoritamab in refractory diffuse large B-cell lymphoma (DLBCL) has been established. However, its safety in dialysis-dependent patients is unclear. A 53-year-old man with refractory DLBCL who had received a series of differ...
Reply to the Letter Regarding "Gut Microbiota and Interorgan Communication Among the Gut, Brain, and Beyond" [0.03%]
关于“肠道微生物群和肠-脑等器官间通讯”的来信的答复
Arina Shigehara,Hiroki Kiyohara,Toshiaki Teratani et al.
Arina Shigehara et al.
Ocular Follicular Lymphoma with Marginal Zone Differentiation: A Diagnostic Pitfall Mimicking MALT Lymphoma [0.03%]
具有边缘区分化的眼部滤泡性淋巴瘤：一种类似于MALT淋巴瘤的诊断陷阱
Takashi Miyachi,Akihiro Kitadate,Wataru Kuroki et al.
Takashi Miyachi et al.
Follicular lymphoma with marginal zone differentiation (FL with MZD) is a rare variant that mimics mucosa-associated lymphoid tissue (MALT) lymphoma. A 64-year-old woman presented with a conjunctival mass that was initially diagnosed as MAL...
Jiro Fujita,Shohei Gaja,Tetsu Chinen et al.
Jiro Fujita et al.